1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Harbin Gloria Pharmaceuticals Co., Ltd

Harbin Gloria Pharmaceuticals Co., Ltd

002437.SZ
Harbin Gloria Pharmaceuticals Co., LtdCN flagShenzhen Stock Exchange
3.03
CNY
+0.07
- -
6.76BMarket Cap
Harbin Gloria Pharmaceuticals Co., Ltd
002437.SZ
(Shenzhen Stock Exchange)

Recent

price

3.03

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
0.31
0.26
0.34
0.62
0.91
1.25
1.37
1.38
2.49
2.3
1.39
1.43
1.41
1.19
1.11
0.97
1.05
Revenue per Share
0.08
0.06
0.08
0.11
0.21
0.31
0.33
0.14
0.06
-1.21
0.18
0.02
-0.13
0.05
0.11
0.17
0.11
Basic EPS, GAAP
-0.07
-0.02
0.03
0.14
0.26
0.2
0.39
0.21
0.48
0.26
-0.01
0.11
0.1
0.11
0.16
0.11
-0.02
Free Cash Flow per Basic Share
- -
0.03
- -
0.08
0.03
0.07
0.12
0.12
0.08
0.08
0.06
0.03
0.03
0.02
- -
- -
- -
Dividend per Share
0.24
0.29
0.36
0.38
0.79
1.02
1.55
1.61
1.64
0.42
0.6
0.51
0.53
0.58
0.73
0.88
0.77
Book Value per Share
1.13
1
1.06
0.79
0.4
-0.3
-0.05
-0.04
0.21
0.34
0.53
0.58
0.5
0.52
0.65
0.81
0.68
Tangible Book Value per Share
1,842
2,087
2,095
2,126
2,100
2,145
2,179
2,198
2,197
2,198
2,198
2,197
2,199
2,200
2,198
2,193
2,199
Basic Weighted Avg Shares
575
546
711
1,308
1,906
2,681
2,984
3,042
5,481
5,054
3,055
3,145
3,108
2,626
2,441
2,135
2,319
Sales/Revenue/Turnover
31.76
20.42
22.3
13.83
26.64
32.09
31.18
18.31
11.58
8.79
-0.57
5.58
4.38
9.37
11.99
12.59
11.84
Operating Margin (%)
16
21
26
62
92
144
155
176
184
181
149
144
130
104
92
91
- -
Depreciation Expense
155
117
165
227
444
665
717
310
126
-2,662
400
45
-291
120
233
377
242
Net Income, GAAP
15.49
14.65
17.92
14.8
16.79
15.11
15.13
17.76
28.04
- -
27.68
37.38
- -
27.2
14.51
6.65
12.12
Effective Tax Rate (%)
26.89
21.39
23.17
17.34
23.28
24.79
24.02
10.18
2.3
-52.67
13.1
1.43
-9.37
4.58
9.54
17.65
10.44
Profit Margin (%)
1,762
1,738
1,720
1,036
95
-1,939
-1,508
-1,244
-1,202
-1,563
-761
-478
-520
-257
54
521
185
Working Capital
- -
30
15
- -
337
300
973
1,455
997
1
11
- -
- -
- -
2
1
1
LT Debt
2,121
2,197
2,361
2,478
3,102
3,473
4,047
4,253
4,448
1,588
1,933
1,979
1,704
1,710
1,973
2,310
2,067
Total Equity
12.1
4.35
5.61
6.26
12.12
12.56
10.5
5.8
5.84
- -
-0.33
3.2
- -
6.37
11.29
11.33
11.33
Return on Invested Capital (%)
40.01
21.23
18.55
24.53
23.28
15.79
12.2
6.28
3.37
- -
14.13
2.93
- -
6.09
12.74
20.43
14.08
Return on Capital (%)
44.39
22.37
24.15
29.11
36.21
34.57
25.68
8.95
3.52
-117.35
35.58
3.7
-25.59
9.83
16.14
21.38
15.23
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
1
71
71
LT Borrowings
- -
- -
- -
LT Finance Leases
2
2
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
2,280
2,247
2,246
Market Capitalization
5,540
5,344
6,267

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
877
947
989
Cash, Cash Equivalents & STI
512
602
653
Accounts Receivable, Net
125
107
114
Inventories
189
186
170
Total Current Liabilities
823
892
804
Payables & Accruals
- -
- -
- -
ST Debt
1
71
71
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
0.49%
4.26%
17.07%
Free Cash Flow
-82.26%
-171.85%
-28.3%
Net Income, GAAP
-325.92%
-164.3%
61.93%
Sales/Revenue/Turnover
1.28%
-6.66%
-12.51%
Total Cash Common Dividend
-24.29%
-50.46%
-87.08%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
593
628
636
583
2,441
2025
551
548
470
- -
2,135
2026
539
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.02
- -
- -
- -
0.11
2025
0.03
- -
- -
- -
0.17
2026
0.04
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Sumitomo Pharma Co., Ltd. (DNPUF)
Herborium Group, Inc. (HBRM)
Golden Biotechnology Corporation (4132.TWO)
Teva Pharmaceutical Industries Limited (TEVJF)
Granules India Limited (GRANULES.NS)
Zhejiang Huahai Pharmaceutical Co., Ltd. (600521.SS)
Business
Harbin Gloria Pharmaceuticals Co., Ltd. (002437.SZ) engages in the research, development, production, and sale of pharmaceutical products primarily in the People's Republic of China. Founded in 2000 and headquartered in Harbin, the company operates in the generic and specialty pharmaceuticals sector, with a diversified portfolio spanning multiple therapeutic areas including cardiac cerebrovascular medications such as sodium creatine phosphate for injection and amlodipine olmesartan ester tablets; skeletal muscle system drugs like cervus and cucumis polypeptide injection; vitamins and minerals including multivitamin injections and compound vitamin injections; urinary system medications; antitumor drugs such as fluorouracil for injection, cyclophosphamide for injection, and pingyangmycin hydrochloride for injection; endocrine medicines like sitagliptin metformin sustained-release tablets; anti-infective drugs including compound cefaclor capsules; respiratory medications; antihistamines; peptic ulcer treatments; and other products encompassing orthopedic medicines, rheumatology drugs, digestive system medicines, liver disease medications, gynecology medications, circulatory system drugs, pediatrics, uropoiesis and reproduction therapies, and immune regulation products. The company maintains production facilities certified by international standards and serves healthcare providers across China, with overseas sales contributing a minor portion of revenue. Recent developments include the completion of an acquisition of an additional 10% stake in subsidiary Harbin Dandelion Pharmaceuticals Co., Ltd. from Harbin Hanjun; a CNY 100 million funding commitment to Guangzhou Gloria Biosciences Co., Ltd.; a planned CNY 200 million (approximately $27.5 million) acquisition of a 70% stake in Sheyang Zhenyang Hospital, marking entry into healthcare services; securing marketing rights for Eisai's mecobalamin injection; and a co-promotion agreement for a lipid-lowering drug. In 2024, the company reported chemical medicine sales of CNY 2.25 billion and traditional Chinese medicine sales of CNY 182 million, reflecting strategic expansion through epitaxial mergers, cooperative agents, independent R&D, and overseas introductions, alongside a pipeline of over 15 pharmaceutical candidates in clinical trials and oncology segment growth of 15% year-over-year.